Page last updated: 2024-12-09

map4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MAP4: partial amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1795545
CHEMBL ID1488784
SCHEMBL ID179781
MeSH IDM0189695

Synonyms (21)

Synonym
gtpl1414
NCGC00024744-01
tocris-0711
map4
NCGC00024744-02
(2s)-2-amino-2-methyl-4-phosphonobutanoic acid
AKOS006272533
(s)-2-amino-2-methyl-4-phosphonobutanoic acid
157381-42-5
CHEMBL1488784
SCHEMBL179781
sr-01000597625
SR-01000597625-1
J-009412
4-phosphono-l-isovaline
DTXSID40935660
Q27083516
(s)-map4
l-isovaline, 4-phosphono-
CS-0020934
HY-101164
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346255Rat mGlu6 receptor (Metabotropic glutamate receptors)2002Current drug targets. CNS and neurological disorders, Jun, Volume: 1, Issue:3
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology.
AID1346251Rat mGlu8 receptor (Metabotropic glutamate receptors)1997Molecular pharmacology, Jan, Volume: 51, Issue:1
Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile.
AID1346251Rat mGlu8 receptor (Metabotropic glutamate receptors)2000Brain research. Molecular brain research, Mar-10, Volume: 76, Issue:1
Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors.
AID1346283Rat mGlu4 receptor (Metabotropic glutamate receptors)1999The Journal of biological chemistry, Apr-09, Volume: 274, Issue:15
Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor.
AID1346263Human mGlu7 receptor (Metabotropic glutamate receptors)2000Naunyn-Schmiedeberg's archives of pharmacology, Dec, Volume: 362, Issue:6
Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]